NCT06966401
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 6 words
- Trial sites expanded: 106 → 120 locations
- Minor Trial sites expanded: 98 → 106 locationsv5
- Minor Trial sites expanded: 87 → 98 locationsv4
- Minor Enrollment target: 600 to 850
- Study sites: 18 to 87
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 18
- Start date changed from estimate of May 2025 to Apr 16, 2025
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Number of Participants with Treatment-emergent Adverse Events (TEAEs)
Timeframe: Baseline through Week 52
Arms and interventions
NBI-1065845Experimental
NBI-1065845 administered orally once a day.
Drugs: NBI-1065845
Sites
120 sites in 23 countries
United States 49, Bulgaria 9, Poland 9, Slovakia 6, Czechia 5, United Kingdom 4, Croatia 3, Finland 3, Latvia 3, Lithuania 3, Netherlands 3, Sweden 3, Australia 2, Belgium 2, Canada 2, Hungary 2, Italy 2, Serbia 2, South Korea 2, Spain 2, Taiwan 2, Estonia 1, Romania 1